WEST LAFAYETTE, Ind. – Purdue University researchers from the College of Pharmacy and College of Engineering are developing a patent-pending treatment that could impact millions of American lives each year.

The Centers for Disease Control and Prevention reports that at least 1.7 million American adults develop sepsis each year; nearly 270,000 die from it. One in three patients who die in a hospital suffers from sepsis. Sepsis occurs when the body’s immune response to an infection or injury is not controlled. Chemicals or proteins released into the blood lead to leaky blood vessels, inflammation, and extensive blood clots. These conditions lead to impaired blood circulation, which can cause organ damage and death.

Yoon Yeo leads a Purdue team developing biocompatible nanoparticles that treat sepsis systemically through intravenous injection. Yeo is Professor and Associate Department Head of Industrial and Physical Pharmacy at the College of Pharmacy. She is also a professor at the Weldon School of Biomedical Engineering. The research was published in the August 2021 issue of peer-reviewed Science Advances.

Yeo said polymyxin B, a traditional antibiotic, can inactivate endotoxins that cause a specific type of sepsis, but may be too toxic for systemic application. For the treatment of sepsis, it has mainly been tested in extracorporeal blood cleansing, which is tedious and time-consuming.

“Our nanoparticle formulations reduce the dose-limiting toxicity of polymyxin B without losing its ability to inactivate endotoxins,” Yeo said.

In mouse models of sepsis, 100% of subjects treated with Purdue’s nanoparticle were protected from excessive inflammation and survived.

“This technology shows promise as a safe and convenient option for patients and physicians,” Yeo said.

Yeo disclosed the nanoparticles to the Purdue Research Foundation’s Technology Commercialization Office, which has filed patent applications with the US Patent and Trademark Office and the European Patent Office to protect intellectual property. For more information on licensing opportunities, contact OTC’s Joe Kasper at [email protected] regarding 2019-YEO-68355.

About the Purdue Research Foundation Technology Commercialization Office

The Purdue Research Foundation’s Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the United States. The services provided by this office support Purdue University’s economic development initiatives and benefit the university’s academic activities through Purdue’s marketing, licensing, and protection. intellectual property. The office is located in the Convergence Center for Innovation and Collaboration in the Discovery Park District at Purdue, adjacent to the Purdue campus. In fiscal year 2021, the bureau reported 159 agreements finalized with 236 technologies signed, 394 disclosures received, and 187 U.S. patents granted. The office is managed by the Purdue Research Foundation, which received the 2019 Innovation and Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. In 2020, IPWatchdog Institute ranked Purdue third nationally for startup creation and in the top 20 for patents. The Purdue Research Foundation is a private, nonprofit foundation established to advance the mission of Purdue University. Contact [email protected] for more information.

About Purdue University

Purdue University is a leading public research institution that develops practical solutions to today’s toughest challenges. Ranked in each of the past four years as one of the 10 most innovative universities in the United States by US News & World Report, Purdue delivers groundbreaking research and groundbreaking discoveries. Committed to hands-on, online, real-world learning, Purdue provides transformative education for all. Committed to affordability and accessibility, Purdue has frozen tuition and most fees at 2012-13 levels, allowing more students than ever to graduate debt-free. Learn how Purdue never stops in the persistent pursuit of the next giant leap at https://stories.purdue.edu.

Writer: Steve Martin, [email protected]

Source: Yoon Yeo, [email protected]